Project Grant R01CA275961
Award Date
2/3/23
Completion Date
12/31/27
Dollars Obligated
$947K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
The National Cancer Institute (NCI) has awarded a 5-year, $431,561 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University to elucidate the role of the HMGA1 chromatin regulator in pancreatic cancer progression and develop novel therapeutic strategies targeting HMGA1 pathways. The research aims to precisely define HMGA1-dependent mechanisms driving tumor progression and the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) using mouse models and...
This Project Grant award of $636,046 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to define the oncogenic potential and therapeutic dependencies of specific KRAS gene variants associated with pancreatic ductal adenocarcinoma (PDAC). The research aims to: Decipher how cell lineage impacts the neoplastic transformation and molecular evolution of epithelial cells in KRAS G12R and G12V mutant PDAC. Define the oncogenic factors...
This $523,480 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Dana-Farber Cancer Institute, Inc. (DFCI) to study mechanisms of resistance to KRAS inhibitor therapy in pancreatic ductal adenocarcinoma (PDAC). The research aims to define how dysregulated iron metabolism and autophagy pathways contribute to adaptive and acquired resistance to KRAS inhibitors, as well as explore targeting iron overload-induced ferroptosis as a...
The National Cancer Institute (NCI) awarded a $103,948 project grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Wayne State University to investigate the role of the Regulator of Chromosome Condensation 1 (RCC1) protein in driving progression of pancreatic ductal adenocarcinoma (PDAC). The research project aims to use state-of-the-art transcriptomics and metabolomics approaches to elucidate how RCC1 alters PDAC metabolic activity and drives tumor progression....
The National Cancer Institute (NCI) awarded a $1,028,232 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Mississippi Medical Center (UMMC) to dissect the roles of Lunatic Fringe (LFNG)-dependent Notch signaling in pancreatic cancer development. The project aims to determine how LFNG-dependent Notch signaling influences pancreatic cancer initiation and progression from different cell types, as well as characterize LFNG-expressing pancreatic cancer cells to identify...
This $602,486 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) aims to explore the feasibility of targeting retrotransposons as a novel approach for improving treatment outcomes for refractory pediatric neuroblastoma and other childhood solid tumors. The 5-year research program, awarded to Health Research, Inc. at the Roswell Park Division, will comprehensively characterize retrotransposon activities in these cancers, investigate the impact...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami aimed at disrupting the interactions between myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF) in pancreatic cancer. The overarching goals are to: Mechanistically dissect the signaling and spatial interactions between MDSC-derived transmembrane TNF and TNFR2-expressing inflammatory CAFs that govern...
This Project Grant award, totaling $719,799, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program. The award supports research to investigate the role of the metabolic enzyme PFKFB4 in regulating the tumor microenvironment and immune function in metastatic triple-negative breast cancer (TNBC). The research aims to: Elucidate the bifunctional mechanisms by which PFKFB4 kinase and phosphatase activities regulate metabolic and genetic...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The National Cancer Institute (NCI) awarded a $268,345 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to develop a novel immunotherapy for pancreatic cancer. The key products and services to be delivered under this 2-year grant include: Interrogating the role of the PSGL-1/VISTA axis in regulating T cell responses to pancreatic tumors. This will involve evaluating the immunologic and therapeutic impact of PSGL-1 blockade on...